MAM Anagh

M Anagh

*This is an algorithmically generated author record based on publicly available information.

M Anagh has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring nature’s potential: A traditional and phytopharmacological review of Amaranthaceae family targeting JAK–STAT signalling pathway

    by M Anagh, P P Uttam, B Bolay

    The Amaranthaceae family, encompassing more than 175 genera and over 2000 species, represents one of the most diverse groups of angiosperms with profound ethnomedicinal, nutritional, pharmacological and ecological significance worldwide. Medicinally important species, including Amaranthus viridis L., Achyranthes bidentata Blume, Alternanthera sessilis (L.) DC. and Celosia argentea L., have been extensively utilised in Ayurveda, Siddha, traditional Chinese medicine (TCM) and numerous indigenous healthcare systems for the management of inflammatory disorders, diabetes mellitus, gastrointestinal diseases, reproductive ailments and wound healing. This critical review comprehensively elucidates the ethnobotanical relevance, phytochemical diversity, nutritional attributes and pharmacological potential of Amaranthaceae species, with particular emphasis on their modulation of the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signalling pathway, a pivotal regulator of inflammation, immunity, cellular proliferation and apoptosis. Phytochemical investigations have revealed an extensive repertoire of bioactive metabolites, including flavonoids, alkaloids, saponins, terpenoids, phenolic acids and betalains, which collectively exhibit potent antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, antimicrobial and immunomodulatory activities. Emerging experimental evidence suggests that several Amaranthaceae-derived phytoconstituents effectively regulate aberrant JAK–STAT signalling, thereby highlighting their potential as promising natural alternatives or complementary adjuncts to synthetic JAK inhibitors for the management of chronic inflammatory and immune-mediated disorders. Beyond their therapeutic applications, numerous species serve as nutrient-dense leafy vegetables and pseudocereals enriched with high-quality proteins, essential amino acids, dietary fibre, vitamins and minerals, contributing substantially to global food and nutritional security. Nevertheless, significant challenges persist regarding phytochemical standardisation, optimisation of bioavailability, comprehensive toxicological assessment, pharmacokinetic characterisation and rigorous clinical validation. Future multidisciplinary investigations integrating advanced phytochemical profiling, molecular pharmacology, systems biology, nanotechnology and well-designed clinical trials are indispensable to accelerate the translational development of Amaranthaceae-derived nutraceuticals and phytopharmaceuticals for inflammatory and immunological diseases.